Drug-eluting Stents Current Events | Drug-eluting Stents News | 10
|
| Page
10 of
29 |
571 Results |
|
|
|
Sort By:
Page Views | Date |
Still puzzling: Best care for the frail and elderly with coronary artery disease
A new study from Duke University Medical Center finds that patients treated solely with medications after suffering from chest pain, heart attack or coronary artery disease are more likely to die during the first year following their initial hospitalization. view more (2008-07-21)
Sport helps prevent teenage drug use
A study of drug-taking and lifestyle among 15-year-olds in England, Ireland, Germany, Italy and the Netherlands has suggested that participation in sport and early intervention in antisocial behaviour, possibly by schools, may be key factors in the prevention of drug use. Dr Paul McArdle, of Newcastle University's Department of Child Health, led... view more... (2001-04-25)
Potential atherosclerosis drug exhibits no harmful side-effects in liver
Researchers have developed and tested a synthetic atherosclerosis drug that can reduce the build-up of dangerous blood vessel plaques without producing the side-effect of fatty liver disease (which leads to its own set of problems like diabetes). The encouraging results of this study in mice could lead to a new type of drug to treat or even... view more... (2009-02-13)
London School of Hygiene to play key role in global collaboration on adverse drug reactions
The London School of Hygiene & Tropical Medicine is to be a key player in the first global research collaboration aimed at identifying the genetic markers related to Adverse Drug Reactions (ADRs). view more (2007-09-27)
Epilepsy drug causes eye problems in over 40 per cent of cases
Vigabatrin, a drug used to treat epilepsy, causes eye problems in over 40 per cent of those prescribed it, shows a study in the Journal of Neurology Neurosurgery and Psychiatry. Vigabatrin was licensed in the UK in 1989 and was the first anti-epileptic drug to come on to the marked since the 1970s. Although effective, it has been associated with... view more... (2002-08-20)
RiboTargets joins Partnership for Structural Biology at the European Synchrotron Radiation Facility
RiboTargets, the structure-based drug discovery company that develops novel cancer and anti-bacterial therapeutics, announced today that it has joined the new Partnership for Structural Biology (PSB) established at the European Synchrotron Radiation Facility (ESRF). Associate membership of the PSB will provide guaranteed access to beamlines at... view more... (2003-01-24)
DNA research taking guesswork out of finding the 'therapeutic window'
It's only spit, but what's inside your saliva may help solve a dosing dilemma facing doctors and patients. view more (2008-10-24)
New medication brings hope of jet lag cure
A team of researchers from Monash University, The Brigham and Women's Hospital (Boston), Harvard Medical School and Vanda Pharmaceuticals has found a new drug with the potential to alleviate jet lag and sleep disorders caused by shift work. view more (2008-12-02)
Structure of key cancer drug target identified
Researchers from Monash's Department of Biochemistry and Molecular Biology have determined the structure of the protein JAK2 kinase, a discovery with huge implications for the design and development of new cancer drugs. view more (2005-10-26)
Adverse drug events reported to FDA appear to have increased markedly
The number of serious adverse drug events reported to the U.S. Food and Drug Administration (FDA) more than doubled between 1998 and 2005, as did deaths associated with adverse drug events. view more (2007-09-11)
Treatment outcomes highlight dangers of extensively drug-resistant tuberculosis
In a retrospective study of 174 tuberculosis patients treated at National Jewish Health (formerly National Jewish Medical and Research Center), patients with extensively-drug-resistant tuberculosis (XDR-TB) were almost eight times as likely to die as patients with multi-drug resistant tuberculosis (MDR-TB). view more (2008-08-07)
Despite some benefit, drug ads can be harmful to your health
While the debate over prescription drug advertising persists, a new study released online in the American Journal of Public Health offers guidelines for improving drug ads in order to minimize potential harm and maximize benefits. view more (2009-11-12)
Stealth particles to target tumors
Stealth nano particles may some day target tumor cells and deliver medication to specific body locations, according to Penn State chemical engineers. view more (2005-09-01)
Doctors may be giving the wrong dosage of adrenaline in an emergency because of labelling
A new study by Cambridge University reveals that doctors treating life-threatening emergencies such as allergy attacks may give the wrong dosage of adrenaline (epinephrine) because of confusing labelling. view more (2008-01-02)
More than 10 percent of adults abuse or become dependent on drugs during their lifetime
Approximately 10.3 percent of U.S. adults appear to have problems with drug use or abuse during their lives, including 2.6 percent who become drug dependent at some point. view more (2007-05-08)
New Oxford Spin-out to Improve on Drug Delivery
Oxford University's latest spin-out company is the drug delivery and glycoprotein specialist Glycoform Ltd, which uses expertise in identifying novel carbohydrate - cell surface receptor- binding properties to develop unique drug targeting systems. The company is developing a novel technology known as LEAPT (Lectin Enzyme Activated Pro-drug... view more... (2002-12-23)
New Insights into the Mechanisms of Rapamycin
Rapamycin is a new drug which is being used for preventing organ rejection in kidney transplant patients. Since it suppresses the immune response and has a strong cell killing effect, it is a highly interesting substance for potential use in other disease areas such as cancer, autoimmune diseases, and diabetes mellitus. A recent publication of the... view more... (2004-04-07)
Doubling of deaths from alcoholic liver disease - drug abuse during 1970s and 1980s may explain why
Middle-aged men could be at increased risk of death from liver disease, as a result of illicit intravenous drug use during the 1970s and 1980s, according to a study published today. view more (2002-07-31)
Pros and Cons of Ecstasy Use
Ecstasy users are generally aware of the health risks that they expose themselves to but seem to reject this knowledge in favour of the benefits they experience from taking the drug. view more (2004-04-19)
Unlicensed and off-label prescribing in children must improve
Many drugs prescribed to children in general practice are either not licensed for use in children ("unlicensed") or are prescribed outside the terms of the product licence ("off-label"). Three studies in this week's BMJ show that unlicensed and off-label prescription of drugs to children is common and carries a high risk of... view more... (2002-05-28)
|
|
| Page
10 of
29 |
571 Results |
|
|
|
Sort By:
Page Views | Date |
|
